A soluble receptor decoy protects rats against anthrax lethal toxin challenge

scientific article published on 10 August 2005

A soluble receptor decoy protects rats against anthrax lethal toxin challenge is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1086/432731
P698PubMed publication ID16107958
P5875ResearchGate publication ID7652620

P50authorMarianne ManchesterQ55190308
R. John CollierQ2123854
P2093author name stringGiuseppe Destito
John A T Young
Diane Thomas
Heather M Scobie
Darran J Wigelsworth
John M Marlett
P433issue6
P407language of work or nameEnglishQ1860
P304page(s)1047-1051
P577publication date2005-08-10
P1433published inJournal of Infectious DiseasesQ4051141
P1476titleA soluble receptor decoy protects rats against anthrax lethal toxin challenge
P478volume192

Reverse relations

cites work (P2860)
Q39958178A dual-purpose protein ligand for effective therapy and sensitive diagnosis of anthrax
Q39124815A human/murine chimeric fab antibody neutralizes anthrax lethal toxin in vitro.
Q34102678A receptor-based switch that regulates anthrax toxin pore formation
Q28469319A viral nanoparticle with dual function as an anthrax antitoxin and vaccine
Q33380169Anthrax edema toxin modulates PKA- and CREB-dependent signaling in two phases.
Q38060730Anthrax lethal toxin and the induction of CD4 T cell immunity
Q30481474Anthrax lethal toxin induces cell death-independent permeability in zebrafish vasculature
Q30830672Anthrax toxin receptor 2 determinants that dictate the pH threshold of toxin pore formation
Q27304959Anthrax toxin receptor 2 functions in ECM homeostasis of the murine reproductive tract and promotes MMP activity
Q34128041Anthrax toxin receptor 2 is expressed in murine and tumor vasculature and functions in endothelial proliferation and morphogenesis
Q28572283Anthrax toxin receptor 2-dependent lethal toxin killing in vivo
Q38132268Anthrax vaccines: present status and future prospects.
Q37404847Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis
Q37262118Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax
Q38760476Anti-virulence Strategies to Target Bacterial Infections
Q37676924Anti-virulence strategies to combat bacteria-mediated disease
Q33506611Bacillus anthracis lethal toxin disrupts TCR signaling in CD1d-restricted NKT cells leading to functional anergy
Q36895609Bacillus anthracis: interactions with the host and establishment of inhalational anthrax.
Q39011436Bidirectional effect of Wnt signaling antagonist DKK1 on the modulation of anthrax toxin uptake.
Q39355381Changing the receptor specificity of anthrax toxin
Q36761999Characterization of the interaction between anthrax toxin and its cellular receptors
Q42363492Constitutive MEK1 Activation Rescues Anthrax Lethal Toxin-Induced Vascular Effects In Vivo
Q40249153Cytotoxic activity of Bacillus anthracis protective antigen observed in a macrophage cell line overexpressing ANTXR1.
Q41114190Defensive strategies of Bacillus anthracis that promote a fatal disease
Q28730606Delayed toxicity associated with soluble anthrax toxin receptor decoy-Ig fusion protein treatment
Q33267360Divalent metal ion coordination by residue T118 of anthrax toxin receptor 2 is not essential for protective antigen binding
Q37115804Efficient neutralization of antibody-resistant forms of anthrax toxin by a soluble receptor decoy inhibitor
Q40395310Expression, Purification, and Biophysical Characterization of a Secreted Anthrax Decoy Fusion Protein in Nicotiana benthamiana
Q38355454Fusion protein of Delta 27LFn and EFn has the potential as a novel anthrax toxin inhibitor
Q34100366Heterodimeric integrin complexes containing beta1-integrin promote internalization and lethality of anthrax toxin
Q33557833Identification of a claudin-4 residue important for mediating the host cell binding and action of Clostridium perfringens enterotoxin
Q30559245Identification of small molecules that inhibit the interaction of TEM8 with anthrax protective antigen using a FRET assay.
Q35436076Imaging tumor endothelial marker 8 using an 18F-labeled peptide
Q34015820Improving the anti-toxin abilities of the CMG2-Fc fusion protein with the aid of computational design
Q90225928Inhibition of Pore-Forming Proteins
Q64255131Inhibition of bacterial toxin recognition of membrane components as an anti-virulence strategy
Q35987872Inhibitors of the Metalloproteinase Anthrax Lethal Factor
Q37314633Molecular decoys: antidotes, therapeutics and immunomodulators
Q40130027Neutralization of staphylococcal enterotoxin B by soluble, high-affinity receptor antagonists
Q34659076Receptors of anthrax toxin and cell entry.
Q36507229Recombinant HSA-CMG2 Is a Promising Anthrax Toxin Inhibitor
Q33258307Recombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine
Q26775093Roles of Anthrax Toxin Receptor 2 in Anthrax Toxin Membrane Insertion and Pore Formation
Q36864660Selection of anthrax toxin protective antigen variants that discriminate between the cellular receptors TEM8 and CMG2 and achieve targeting of tumor cells
Q58091462Structural basis for anthrax toxin receptor 1 recognition by Seneca Valley Virus
Q37996325Targeting bacterial toxins
Q34732577Targeting the anthrax receptors, TEM-8 and CMG-2, for anti-angiogenic therapy
Q42397574The International Bacillus anthracis, B. cereus, and B. thuringiensis Conference, "Bacillus-ACT05".
Q27662859The Structure of Tumor Endothelial Marker 8 (TEM8) Extracellular Domain and Implications for Its Receptor Function for Recognizing Anthrax Toxin
Q41954911Toxicity of anthrax toxin is influenced by receptor expression
Q35985908Transcriptional stimulation of anthrax toxin receptors by anthrax edema toxin and Bacillus anthracis Sterne spore
Q33933081Tumor endothelium marker-8 based decoys exhibit superiority over capillary morphogenesis protein-2 based decoys as anthrax toxin inhibitors
Q46720421Whole-cell voltage clamp measurements of anthrax toxin pore current
Q61797224Why Are Botulinum Neurotoxin-Producing Bacteria So Diverse and Botulinum Neurotoxins So Toxic?

Search more.